Therapy Detail

Therapy Name SYM004
Synonyms
Therapy Description

Symphogen (Sym004) is comprised of two antibodies that bind EGFR and prevent ligand binding, which may prevent downstream signaling and result in decreased tumor cell proliferation (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
SYM004 Symphogen EGFR Antibody 27 Symphogen (Sym004) is comprised of two antibodies that bind EGFR and prevent ligand binding, which may prevent downstream signaling and result in decreased tumor cell proliferation (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
EGFR positive lung non-small cell carcinoma predicted - sensitive SYM004 Preclinical - Cell line xenograft Actionable In a preclinical study, SYM004 demonstrated efficacy in cell line xenograft models of Erbitux (cetuximab)-resistant non-small cell lung cancer (PMID: 24204198). 24204198
EGFR positive colorectal cancer sensitive SYM004 Phase I Actionable In a Phase I study, 13% (5/39) of patients with metastatic colorectal cancer resistant to EGFR therapy had a partial response to SYM004 while 44% (17/39) demonstrated tumor regression (PMID: 25962717). 25962717
EGFR S492R colorectal cancer sensitive SYM004 Phase I Actionable In a Phase I study, a colorectal cancer patient harboring EGFR S492R demonstrated a partial response when treated with SYM004 (PMID: 25962717). 25962717
EGFR G465R colorectal cancer sensitive SYM004 Case Reports/Case Series Actionable In a clinical study, a patient with Erbitux (cetuximab)-resistant metastatic colorectal cancer harboring EGFR G465R demonstrated stable disease for 15 weeks following treatment with SYM004 (PMID: 26888827). 26888827
EGFR G465R colorectal cancer sensitive SYM004 Preclinical - Cell line xenograft Actionable In a preclinical study, SYM004 inhibited EGFR downstream signaling and proliferation of a colorectal cancer cell line harboring EGFR G465R in culture, and induced tumor regression in xenograft models (PMID: 26888827). 26888827
EGFR K467T Advanced Solid Tumor predicted - sensitive SYM004 Preclinical - Cell culture Actionable In a preclinical study, SYM004 inhibited phosphorylation of EGFR in cells expressing EGFR K467T in culture (PMID: 26888827). 26888827
EGFR R451C Advanced Solid Tumor predicted - sensitive SYM004 Preclinical - Cell culture Actionable In a preclinical study, SYM004 inhibited phosphorylation of EGFR in cells expressing EGFR R451C in culture (PMID: 26888827). 26888827
NRAS mutant colorectal cancer predicted - resistant SYM004 Preclinical - Pdx Actionable In a preclinical study, patient-derived xenograft (PDX) models of colorectal cancer harboring KRAS, NRAS or BRAF mutations demonstrated poor response to SYM004 treatment compared to wild-type models (PMID: 29423521). 29423521
BRAF mutant colorectal cancer predicted - resistant SYM004 Preclinical - Pdx Actionable In a preclinical study, patient-derived xenograft (PDX) models of colorectal cancer harboring KRAS, NRAS or BRAF mutations demonstrated poor response to SYM004 treatment compared to wild-type models (PMID: 29423521). 29423521

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status
NCT03549338 Phase II Modotuximab Futuximab SYM004 Sym004 Versus Futuximab or Modotuximab in Patients With mCRC Terminated
NCT02083653 Phase II SYM004 Fluorouracil Capecitabine Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer Completed
NCT02540161 Phase II SYM004 Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma Active, not recruiting
NCT02965417 Phase II SYM004 Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients Withdrawn


Additional content available in CKB BOOST